Editas Medicine (EDIT) Cash & Current Investments (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash & Current Investments data on file, last reported at $146.6 million in Q4 2025.

• On a quarterly basis, Cash & Current Investments fell 45.67% year-over-year to $146.6 million in Q4 2025; TTM through Dec 2025 was $146.6 million, a 45.67% decrease from a year earlier, with the FY2025 full-year figure at $146.6 million, down 45.67% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $146.6 million, down from $165.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for EDIT reached as high as $625.3 million in Q1 2021 and fell as low as $146.6 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $362.2 million across 5 years, with a median of $333.7 million in 2022.
• Across the five-year window, Cash & Current Investments surged 50.69% in 2021 and slumped 45.67% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $499.8 million in 2021, then tumbled by 31.12% to $344.3 million in 2022, then dropped by 6.15% to $323.1 million in 2023, then decreased by 16.46% to $269.9 million in 2024, then slumped by 45.67% to $146.6 million in 2025.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $146.6 million in Q4 2025, $165.6 million in Q3 2025, and $178.5 million in Q2 2025.